May 01, 2025 Press Release for Alnylam


Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
May 01, 2025
− Achieved First Quarter 2025 Global Net Product Revenues of
−
− AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators –
− Approval of Qfitlia™ Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered RNAi Therapeutic Approved by
− Reiterates 2025 Financial Guidance, Including Combined Net Product Revenues of
“2025 is off to a remarkable start, having ended the first quarter with
First Quarter 2025 and Recent Significant Business Highlights
Commercial Performance
Total TTR: AMVUTTRA® (vutrisiran) & ONPATTRO® (patisiran)
-
Achieved global net product revenues for AMVUTTRA and ONPATTRO for the first quarter of
$310 million and$49 million , respectively, representing 36% growth compared to Q1 2024.
Total Rare: GIVLAARI® (givosiran) & OXLUMO® (lumasiran)
-
Achieved global net product revenues for GIVLAARI and OXLUMO for the first quarter of
$67 million and$42 million , respectively, representing 8% growth compared to Q1 2024.
R&D Highlights
-
Strong progress making AMVUTTRA available for ATTR-CM in various global markets.
-
Received
U.S. FDA approval of the supplemental New Drug Application (sNDA) for AMVUTTRA for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. -
Received approval from ANVISA (
Brazilian Health Regulatory Agency ) for ATTR-CM. -
Received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) recommending approval of vutrisiran for the treatment of ATTR-CM. -
Marketing authorization applications based on data from the landmark HELIOS-B Phase 3 clinical trial are currently under review by several global health agencies including the
Japanese Pharmaceuticals andMedical Devices Agency (PMDA).
-
Received
-
Presented new data from HELIOS-B at the
American College of Cardiology Scientific Session 2025, further supporting vutrisiran’s compelling therapeutic profile, including:- Echocardiographic data demonstrating that treatment with vutrisiran led to significant improvements in diastolic function and attenuation of declines in left ventricular (LV) and right ventricular (RV) systolic function at Month 18, compared to placebo. HELIOS-B included the largest systematic echocardiographic study conducted to date in an ATTR pivotal trial.
-
An exploratory subgroup analysis demonstrating that vutrisiran reduced all-cause mortality and recurrent cardiovascular events compared to placebo across a range of baseline heart failure severities in patients with ATTR-CM. These data were also published in the
Journal of the American College of Cardiology . -
A separate analysis confirming that vutrisiran significantly maintained or improved functional capacity, and patient-reported health status and quality of life, compared to placebo over 30 months. These data were also published in the
Journal of the American College of Cardiology .
-
Presented updates from the Company’s robust pipeline and organic platform at R&D Day.
-
Disclosed two new clinical programs:
- ALN-6400, targeting liver-derived plasminogen, which could represent a universal hemostatic agent for the treatment of bleeding disorders without the risk of thrombosis.
-
ALN-4324, targeting GRB14, a potential insulin sensitizer for the treatment of type 2 diabetes.
Alnylam announces today that a Phase 1 clinical trial for ALN-4324 has been initiated.
- Shared encouraging data from our expanding neuroscience franchise, including an update on the new ALN-HTT02 program, which has a highly differentiated exon-1-targeting approach to lower huntingtin (HTT) for Huntington’s disease.
- Presented new preclinical data on delivery solutions with best-in-class potential for adipose, muscle, heart, and kidney tissue and for crossing the blood-brain barrier, supporting Alnylam’s aspiration to unlock every major tissue for RNAi therapeutics by 2030.
-
Disclosed two new clinical programs:
Alnylam’s partner, Sanofi, received
Key Upcoming Events
Financial Results for the Quarter Ended
|
Three Months Ended
|
|
Change, % |
|||||||
(In thousands, except per share amounts and percentages) |
|
2025 |
|
|
|
2024 |
|
|
||
Total revenues |
$ |
594,189 |
|
|
$ |
494,333 |
|
|
20 |
% |
GAAP Income (loss) from operations |
$ |
18,077 |
|
|
$ |
(43,435 |
) |
|
(142 |
)% |
Non-GAAP Income from operations |
$ |
74,789 |
|
|
$ |
1,912 |
|
|
* |
|
GAAP Net loss per common share — basic and diluted |
$ |
(0.44 |
) |
|
$ |
(0.52 |
) |
|
(15 |
)% |
Non-GAAP Net loss per common share — basic and diluted |
$ |
(0.01 |
) |
|
$ |
(0.16 |
) |
|
(94 |
)% |
* Indicates the percentage change period over period is greater than 500%. |
For an explanation of our use of non-GAAP financial measures, refer to the “Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measure, see the tables at the end of this press release.
Revenue Summary
|
Three Months Ended
|
|
Change, % |
|
Change at
|
||||||
(In thousands, except percentages) |
2025 |
|
2024 |
|
|
||||||
Net product revenues: |
|
|
|
|
|
|
|
||||
Total TTR net product revenues |
$ |
359,481 |
|
$ |
264,458 |
|
36 |
% |
|
38 |
% |
Total Rare net product revenues |
|
109,057 |
|
|
100,705 |
|
8 |
% |
|
11 |
% |
Total net product revenues |
|
468,538 |
|
|
365,163 |
|
28 |
% |
|
30 |
% |
Net revenues from collaborations: |
|
|
|
|
|
|
|
||||
Roche |
|
17,056 |
|
|
74,680 |
|
(77 |
)% |
|
(77 |
)% |
Regeneron Pharmaceuticals |
|
51,039 |
|
|
26,764 |
|
91 |
% |
|
91 |
% |
Novartis AG |
|
— |
|
|
14,516 |
|
(100 |
)% |
|
(100 |
)% |
Other |
|
31,090 |
|
|
2,588 |
|
* |
|
* |
||
Total net revenues from collaborations |
|
99,185 |
|
|
118,548 |
|
(16 |
)% |
|
(16 |
)% |
Royalty revenue |
|
26,466 |
|
|
10,622 |
|
149 |
% |
|
149 |
% |
Total revenues |
$ |
594,189 |
|
$ |
494,333 |
|
20 |
% |
|
22 |
% |
* Indicates the percentage change period over period is greater than 500% |
|||||||||||
** Change at constant exchange rates, or CER, represents growth calculated as if exchange rates had remained unchanged from those used during the three months ended |
Net Product Revenues
-
Net product revenues increased 28% and 30% at actual currency and CER, respectively, during the three months ended
March 31, 2025 , as compared to the same period in 2024, due to growth from AMVUTTRA driven by increased patient demand, partially offset by a decrease in ONPATTRO due to patient switches to AMVUTTRA, as well as an increased number patients on GIVLAARI.
Net Revenues from Collaborations
-
Net revenues from collaborations decreased during the three months ended
March 31, 2025 , as compared to the same period in 2024, primarily due to recognition of$65.0 million of revenue associated with a milestone under our Roche Collaboration from dosing the first patient in the zilebesiran KARDIA-3 clinical trial during the three months endedMarch 31, 2024 , which did not reoccur during the three months endedMarch 31, 2025 . This was partially offset by increased revenue recognized in connection with our Regeneron Collaboration during the three months endedMarch 31, 2025 as a result of an increase in activities under our licensed programs and recognition of a$30.0 million payment in connection with the amendment to our agreement with Vir Biotechnology, Inc. inMarch 2025 .
Operating Expense Summary
|
Three Months Ended
|
|
Change, % |
|||||||
(In thousands, except percentages) |
|
2025 |
|
|
|
2024 |
|
|
||
Cost of goods sold |
$ |
70,183 |
|
|
$ |
54,613 |
|
|
29 |
% |
% of net product revenues |
|
15.0 |
% |
|
|
15.0 |
% |
|
0 |
% |
Cost of collaborations and royalties |
$ |
858 |
|
|
$ |
11,363 |
|
|
(92 |
)% |
|
$ |
265,122 |
|
|
$ |
260,995 |
|
|
2 |
% |
|
$ |
241,324 |
|
|
$ |
241,780 |
|
|
0 |
% |
GAAP Selling, general and administrative expenses |
$ |
239,949 |
|
|
$ |
210,797 |
|
|
14 |
% |
Non-GAAP Selling, general and administrative expenses |
$ |
207,035 |
|
|
$ |
184,665 |
|
|
12 |
% |
Cost of Goods Sold
-
Cost of goods sold as a percentage of net product revenues was consistent during the three months ended
March 31, 2025 , as compared to the same period in 2024.
Research & Development (R&D) Expenses
-
GAAP R&D expenses increased during the three months ended
March 31, 2025 , as compared to the same period in 2024, primarily due to:
-
increased stock-based compensation expense; and
- increased clinical trial expenses primarily associated with zilebesiran in the KARDIA-3 clinical trial and mivelsiran in the cAPPRicorn-1 clinical trial due to increased Phase 2 activities, as well as startup activities and other clinical trial expenses associated with zilebesiran in the KARDIA-6 cardiovascular outcomes trial and nucresiran in the TRITON-CM Phase 3 clinical trial in patients with ATTR amyloidosis with cardiomyopathy.
-
increased stock-based compensation expense; and
Partially offset by:
- decreased expenses within other clinical programs, specifically the HELIOS-B Phase 3 clinical trial of vutrisiran due to the wind-down of clinical activities.
Non-GAAP R&D expenses remained consistent during the three months ended
Selling, General & Administrative (SG&A) Expenses
-
GAAP and non-GAAP SG&A expenses increased during the three months ended
March 31, 2025 , as compared to the same period in 2024, primarily due to increased marketing investment associated with the promotion of our TTR therapies and increased employee compensation expenses.
Other Financial Highlights
Interest expense
-
Interest expense for the three months ended
March 31, 2025 of$38.6 million included interest of$35.0 million attributed to the liability related to the sale of future Leqvio royalties.
Other expense, net
-
Other expense, net for the three months ended
March 31, 2025 of$59.7 million included a charge associated with the change in fair value of the development derivative liability of$58.9 million , attributed to valuation updates primarily driven by the regulatory approval of AMVUTTRA for the treatment ATTR-CM.
Provision for income taxes
-
During the three months ended
March 31, 2025 , we recorded a provision for income taxes of$15.9 million , primarily due to income generated inSwitzerland . We will utilize deferred tax assets inSwitzerland to offset current cash tax liabilities and will continue to maintain a full valuation allowance against our net deferred tax assets in theU.S. and certain deferred tax assets inSwitzerland .
Financial position
-
Cash, cash equivalents and marketable securities were
$2.63 billion as ofMarch 31, 2025 , as compared to$2.69 billion as ofDecember 31, 2024 , with the decrease primarily driven by operating activities. -
Net cash used in operating activities for the three months ended
March 31, 2025 of$118.3 million , included$61.7 million of payments associated with the liability related to the sale of future Leqvio royalties allocated to interest. -
Net cash provided by financing activities for the three months ended
March 31, 2025 of$44.1 million , included$5.3 million of payments associated with an achieved development milestone for the development derivative liability.
A reconciliation of our GAAP to non-GAAP financial results for the quarter is included in the tables at the end of this press release.
2025 Financial Guidance
Full year 2025 financial guidance is reiterated and consists of the following:
Total TTR net product revenues (AMVUTTRA, ONPATTRO)1 |
|
|
Total Rare net product revenues (GIVLAARI, OXLUMO) |
|
|
Total net product revenues |
|
|
Net product revenues growth vs. 2024 at currency exchange rates as of |
|
25% to 37% |
Net product revenues growth vs. 2024 at constant exchange rates3 |
|
26% to 39% |
Net revenues from collaborations and royalties4 |
|
|
Non-GAAP R&D and SG&A expenses5 |
|
|
Non-GAAP Operating income5 |
|
Achieve profitability |
|
|
|
1Assumes approvals and launches of AMVUTTRA for ATTR-CM in |
||
2Full-year 2025 guidance utilizing currency exchange rates as of |
||
3Representing growth calculated as if the exchange rates had remained unchanged from those used in 2024, which is a non-GAAP financial measure |
||
4Net revenues from collaborations assume achievement of |
||
5Primarily excludes |
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including expenses adjusted to exclude certain non-cash expenses and non-recurring gains or losses outside the ordinary course of the Company’s business. These measures are not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies.
The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are stock-based compensation expenses and realized and unrealized gains or losses on marketable equity securities. The Company has excluded the impact of stock-based compensation expense, which may fluctuate from period to period based on factors including the variability associated with performance-based grants for stock options and restricted stock units and changes in the Company’s stock price, which impacts the fair value of these awards. The Company has excluded the impact of the realized and unrealized gains or losses on marketable equity securities because the Company does not believe these adjustments accurately reflect the performance of the Company’s ongoing operations for the period in which such gains or losses are reported, as their sole purpose is to adjust amounts on the balance sheet.
Percentage changes in revenue growth at CER are presented excluding the impact of changes in foreign currency exchange rates for investors to understand the underlying business performance. The current period’s foreign currency revenue values are converted into
The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Company’s financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance and are better able to compare the Company’s performance between periods. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between GAAP and non-GAAP measures is provided later in this press release.
Conference Call Information
Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future via conference call on
About AMVUTTRA® (vutrisiran)
AMVUTTRA® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection by a healthcare professional, AMVUTTRA is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults and is approved in the
About ONPATTRO® (patisiran)
ONPATTRO is an RNAi therapeutic that is approved in
About GIVLAARI® (givosiran)
GIVLAARI (givosiran) is an RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) approved in
About OXLUMO® (lumasiran)
OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1). HAO1 encodes glycolate oxidase (GO). Thus, by silencing HAO1 and depleting the GO enzyme, OXLUMO inhibits production of oxalate – the metabolite that directly contributes to the pathophysiology of PH1. OXLUMO utilizes Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index. OXLUMO has received regulatory approvals from the
About LNP Technology
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About
Alnylam Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding Alnylam’s expectations regarding the prospects for the launch of AMVUTTRA for the treatment of ATTR-CM in the
This release discusses investigational RNAi therapeutics and uses of previously approved RNAi therapeutics in development and is not intended to convey conclusions about efficacy or safety as to those investigational therapeutics or uses. There is no guarantee that any investigational therapeutics or expanded uses of commercial products will successfully complete clinical development or gain health authority approval.
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except per share amounts) |
|||||||
|
|
|
|
||||
ASSETS |
(Unaudited) |
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
1,019,654 |
|
|
$ |
966,428 |
|
Marketable debt securities |
|
1,605,368 |
|
|
|
1,719,920 |
|
Marketable equity securities |
|
7,200 |
|
|
|
8,156 |
|
Accounts receivable, net |
|
418,035 |
|
|
|
405,308 |
|
Inventory |
|
65,581 |
|
|
|
78,509 |
|
Prepaid expenses and other current assets |
|
152,420 |
|
|
|
116,964 |
|
Total current assets |
|
3,268,258 |
|
|
|
3,295,285 |
|
Property, plant and equipment, net |
|
498,684 |
|
|
|
502,784 |
|
Operating lease right-of-use assets |
|
197,233 |
|
|
|
191,148 |
|
Deferred tax assets |
|
107,224 |
|
|
|
116,863 |
|
Restricted investments |
|
68,592 |
|
|
|
68,593 |
|
Other assets |
|
73,820 |
|
|
|
65,310 |
|
Total assets |
$ |
4,213,811 |
|
|
$ |
4,239,983 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
97,399 |
|
|
$ |
88,415 |
|
Accrued expenses |
|
704,165 |
|
|
|
793,692 |
|
Operating lease liabilities |
|
46,011 |
|
|
|
41,886 |
|
Deferred revenue |
|
28,160 |
|
|
|
55,481 |
|
Liability related to the sale of future royalties |
|
81,793 |
|
|
|
113,018 |
|
Development derivative liability |
|
118,095 |
|
|
|
93,780 |
|
Total current liabilities |
|
1,075,623 |
|
|
|
1,186,272 |
|
Operating lease liabilities, net of current portion |
|
230,061 |
|
|
|
229,541 |
|
Convertible debt |
|
1,025,566 |
|
|
|
1,024,621 |
|
Liability related to the sale of future royalties, net of current portion |
|
1,338,821 |
|
|
|
1,334,353 |
|
Development derivative liability, net of current portion |
|
422,434 |
|
|
|
393,139 |
|
Other liabilities |
|
5,871 |
|
|
|
4,969 |
|
Total liabilities |
|
4,098,376 |
|
|
|
4,172,895 |
|
Stockholders' equity: |
|
|
|
||||
Preferred stock, |
|
— |
|
|
|
— |
|
Common stock, |
|
1,303 |
|
|
|
1,293 |
|
Additional paid-in capital |
|
7,496,876 |
|
|
|
7,388,061 |
|
Accumulated other comprehensive loss |
|
(37,517 |
) |
|
|
(34,518 |
) |
Accumulated deficit |
|
(7,345,227 |
) |
|
|
(7,287,748 |
) |
Total stockholders' equity |
|
115,435 |
|
|
|
67,088 |
|
Total liabilities and stockholders' equity |
$ |
4,213,811 |
|
|
$ |
4,239,983 |
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) |
|||||||
|
Three Months Ended |
||||||
|
|
|
|
||||
Statements of Operations |
|
|
|
||||
Revenues: |
|
|
|
||||
Net product revenues |
$ |
468,538 |
|
|
$ |
365,163 |
|
Net revenues from collaborations |
|
99,185 |
|
|
|
118,548 |
|
Royalty revenue |
|
26,466 |
|
|
|
10,622 |
|
Total revenues |
|
594,189 |
|
|
|
494,333 |
|
Operating costs and expenses: |
|
|
|
||||
Cost of goods sold |
|
70,183 |
|
|
|
54,613 |
|
Cost of collaborations and royalties |
|
858 |
|
|
|
11,363 |
|
Research and development |
|
265,122 |
|
|
|
260,995 |
|
Selling, general and administrative |
|
239,949 |
|
|
|
210,797 |
|
Total operating costs and expenses |
|
576,112 |
|
|
|
537,768 |
|
Income (loss) from operations |
|
18,077 |
|
|
|
(43,435 |
) |
Other (expense) income: |
|
|
|
||||
Interest expense |
|
(38,646 |
) |
|
|
(35,253 |
) |
Interest income |
|
28,673 |
|
|
|
29,645 |
|
Other expense, net |
|
(49,700 |
) |
|
|
(14,544 |
) |
Total other expense, net |
|
(59,673 |
) |
|
|
(20,152 |
) |
Loss before income taxes |
|
(41,596 |
) |
|
|
(63,587 |
) |
Provision for income taxes |
|
(15,883 |
) |
|
|
(2,348 |
) |
Net loss |
$ |
(57,479 |
) |
|
$ |
(65,935 |
) |
Net loss per common share — basic and diluted |
$ |
(0.44 |
) |
|
$ |
(0.52 |
) |
Weighted-average common shares used to compute basic and diluted net loss per common share |
|
129,676 |
|
|
|
126,138 |
|
RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES (In thousands, except per share amounts) (Unaudited) |
|||||||
|
Three Months Ended |
||||||
|
|
|
|
||||
Reconciliation of GAAP to |
|
|
|
||||
|
$ |
265,122 |
|
|
$ |
260,995 |
|
Less: Stock-based compensation expenses |
|
(23,798 |
) |
|
|
(19,215 |
) |
|
$ |
241,324 |
|
|
$ |
241,780 |
|
|
|
|
|
||||
Reconciliation of GAAP to Non-GAAP Selling, general and administrative: |
|
|
|
||||
GAAP Selling, general and administrative |
$ |
239,949 |
|
|
$ |
210,797 |
|
Less: Stock-based compensation expenses |
|
(32,914 |
) |
|
|
(26,132 |
) |
Non-GAAP Selling, general and administrative |
$ |
207,035 |
|
|
$ |
184,665 |
|
|
|
|
|
||||
Reconciliation of GAAP to Non-GAAP Income (loss) from operations: |
|||||||
GAAP Income (loss) from operations |
$ |
18,077 |
|
|
$ |
(43,435 |
) |
Add: Stock-based compensation expenses |
|
56,712 |
|
|
|
45,347 |
|
Non-GAAP Operating income |
$ |
74,789 |
|
|
$ |
1,912 |
|
|
|
|
|
||||
Reconciliation of GAAP to Non-GAAP Net loss: |
|
|
|
||||
GAAP Net loss |
$ |
(57,479 |
) |
|
$ |
(65,935 |
) |
Add: Stock-based compensation expenses |
|
56,712 |
|
|
|
45,347 |
|
Add: Unrealized loss (gain) on marketable equity securities |
|
956 |
|
|
|
(78 |
) |
Less: Income tax effect of GAAP to non-GAAP reconciling items |
|
(1,476 |
) |
|
|
— |
|
Non-GAAP Net loss |
$ |
(1,287 |
) |
|
$ |
(20,666 |
) |
|
|
|
|
||||
Reconciliation of GAAP to Non-GAAP Net loss per common share - basic and diluted: |
|||||||
GAAP Net loss per common share — basic and diluted |
$ |
(0.44 |
) |
|
$ |
(0.52 |
) |
Add: Stock-based compensation expenses |
|
0.44 |
|
|
|
0.36 |
|
Add: Unrealized loss (gain) on marketable equity securities |
|
0.01 |
|
|
|
— |
|
Less: Income tax effect of GAAP to non-GAAP reconciling items |
|
(0.01 |
) |
|
|
— |
|
Non-GAAP Net loss per common share — basic and diluted |
$ |
(0.01 |
) |
|
$ |
(0.16 |
) |
Please note that the figures presented above may not sum exactly due to rounding |
RECONCILIATION OF GAAP TO NON-GAAP PRODUCT REVENUE GROWTH AT CONSTANT CURRENCY (Unaudited) |
||
|
|
|
|
Three Months Ended |
|
Total TTR net product revenue growth, as reported |
36 |
% |
Add: Impact of foreign currency translation |
2 |
|
Total TTR net product revenue growth at constant currency |
38 |
% |
|
|
|
Total Rare net product revenue growth, as reported |
8 |
% |
Add: Impact of foreign currency translation |
3 |
|
Total Rare net product revenue growth at constant currency |
11 |
% |
|
|
|
Total net product revenue growth, as reported |
28 |
% |
Add: Impact of foreign currency translation |
2 |
|
Total net product revenue growth at constant currency |
30 |
% |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250501732343/en/
(Investors and Media)
617-682-4340
(Investors)
617-551-8276
Source:
For Media Inquiries, please contact:
Christine Lindenboom
Chief Corporate Communications Officer media@alnylam.com 617-682-4340
For Investor Inquiries, please contact:
Josh Brodsky
VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276
MEDIA KIT
Essential assets and documents related to Alnylam